Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia

NCT04335305 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT04335305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04335305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Terminated
Start date
April 9, 2020
Completion date
June 21, 2021
Enrollment
12 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, pneumonia, viral